Tier 2 — strong

Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3 as an Adjuvant Therapy for Mild to Moderate Symptoms of COVID-19-Results From a Pilot Open-Label, Randomized Controlled Trial

Amjad Khan, Somia Iqtadar, Sami Ullah Mumtaz, Michael Heinrich, Domingo A Pascual-Figal, Shona Livingstone, Sajid Abaidullah
Frontiers in pharmacology 2022 13:898062

Bibliography

PubMed
PMID 35747751
PubMed Central
PMC9211374
DOI
10.3389/fphar.2022.898062
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
Reported disclosure: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Study snapshot

DesignRandomized open-label adjunctive pilot trial
ModelHuman intervention research
Sample50 COVID-19 outpatients; 25 per group
InterventionCurcumin 168 mg, quercetin 260 mg and vitamin D3 9 micrograms/day with usual care
Duration14 days; principal comparison after 7 days
EndpointsInflammatory measures; Symptoms and quality of life

What the study showed, in plain terms

Published in 2022, this source examined immunity and respiratory health. Design: Randomized open-label adjunctive pilot trial. Sample/model: 50 COVID-19 outpatients; 25 per group. The exposure or intervention was Curcumin 168 mg, quercetin 260 mg and vitamin D3 9 micrograms/day with usual care. Follow-up or treatment period: 14 days; principal comparison after 7 days.

Viral-test negativity and CRP favored the combination. Symptom-resolution differences were not significant.

Small open-label multi-ingredient trial with older usual-care regimens. Benefits cannot be attributed to quercetin alone.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Immune Health, Colds and COVID-19. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Viral-test negativity and CRP favored the combination.
  • Symptom-resolution differences were not significant.
  • The recorded outcome domains were Inflammatory measures; Symptoms and quality of life.
  • The result applies to the tested exposure: Curcumin 168 mg, quercetin 260 mg and vitamin D3 9 micrograms/day with usual care; 14 days; principal comparison after 7 days.

What this study can and cannot tell us

  • Small open-label multi-ingredient trial with older usual-care regimens. Benefits cannot be attributed to quercetin alone.
  • Without a sufficiently blinded concurrent control, time effects, expectations, co-interventions and regression toward the mean can explain part of an apparent improvement.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Immune Preconditioning with Oral Quercetin Supplement and COVID-19 mRNA Vaccine Responses: A Randomized, Double-Blind, Placebo-Controlled Trial
Shokichi Takahama et al. · The Journal of nutrition · 2026
Tier 2
The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial
Mojtaba Shohan et al. · European journal of pharmacology · 2022
Tier 2
Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomized clinical trial
Francesco Di Pierro et al. · Frontiers in pharmacology · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology